ORMP · Oramed Pharmaceuticals Inc
United States · RS rating 57 · As of 2026-11-03
| Price | 4.00 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 57 / 32 / 51 / 91 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 37 / 39 / 58 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +102.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +25.1% |
| Market cap (USD) | $155.3M |